Beta
ManageSearchChatDiscover
352431

XANTUS-EL: A Real-World, Prospective, Observational Study of Patients Treated With Rivaroxaban For Stroke Prevention In Atrial Fibrillation In Eastern Europe, Middle East, Africa

Article

Last updated: 29 Dec 2024

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

The real-world, international, prospective, observational XANTUS study demonstrated low rates of stroke
and major bleeding in an unselected atrial fibrillation (AF) patient population treated with rivaroxaban in routine
clinical practice in Europe, Canada and Israel. XANTUS-EL is a sister study to XANTUS with the aim to
investigate the safety and effectiveness of rivaroxaban in routine clinical use in patients with AF in Eastern Europe,
Middle East, Africa and Latin America.

DOI

10.21608/cvrepj.2017.352431

Volume

1

Article Issue

1

Related Issue

47389

Issue Date

2017-06-01

Receive Date

2024-04-29

Publish Date

2017-06-01

Print ISSN

2636-4204

Online ISSN

2636-4212

Article File

CVREPJ3524311496268000.pdf

PDF . 258.5kB

Link

https://cvrepj.journals.ekb.eg/article_352431.html

Detail API

https://cvrepj.journals.ekb.eg/service?article_code=352431

Order

352,431

Type

Abstracts

Type Code

3,139

Publication Type

Journal

Publication Title

Cardiovascular Research Prove Journal

Publication Link

https://cvrepj.journals.ekb.eg/

MainTitle

XANTUS-EL: A Real-World, Prospective, Observational Study of Patients Treated With Rivaroxaban For Stroke Prevention In Atrial Fibrillation In Eastern Europe, Middle East, Africa And Latin America

Details

Type

Article

Created At

20 Dec 2024